Gene-Editing Startup Raises $120 Million to Apply CRISPR to Medicine
A company started by several gene-editing pioneers gets new funding to develop treatments for blood cancers, eye diseases, and sickle-cell anemia.
CRISPR provides a far easier and more specific way to edit genes than has been previously available.
Editas Medicine, a company at the forefront of developing the gene-editing technology known as CRISPR, has raised $120 million to create new treatments for conditions including cancer, retinal disease, and sickle-cell anemia.
Monday’s announcement reflects a surge of interest in CRISPR, a technology that is only a few years old. It also serves to clarify the goals and strategy of Editas, which was founded by some of the most prominent inventors of the gene-editing system, including Feng Zhang, a researcher at the Broad Institute of Harvard and MIT. “We’re here to make medicines,” Katrine Bosley, Editas’s CEO, declared in an interview at the company’s offices in Cambridge, Massachusetts.
The new group of investors was led by Boris Nikolic, who was Bill Gates’s chief science and technology advisor at the Bill & Melinda Gates Foundation and is managing director of the investment company Bng0. Editas confirmed that Gates was also among the new investors, as are several other wealthy individuals whom the company declined to identify.
Editas, which had previously raised $43 million before this latest round, is one of several private biotechnology companies that have been amassing cash in order to create new types of treatments. Earlier this year, for instance, the biotechnology company Moderna Therapeutics raised $450 million. Juno Therapeutics—which is trying to treat cancers by genetically engineering T cells, a key part of the immune system—raised more than $300 million before going public this year.
CRISPR is particularly promising in making precise changes in cells. T cells taken from a patient could be edited and then infused back into a patient’s body, for example—an approach that Editas is developing through a partnership with Juno. Or cells could be fixed and put back in the blood of a patient with sickle-cell anemia.
Such treatments, however, are in their early days. Editas is not yet running clinical trials involving CRISPR-edited cells. “We don’t want to get out there so fast with patients when we’re not ready, we don’t have the programs yet,” said Bosley.
In addition to using T cells in treating blood cancers, a second major project Bosley will discuss involves treating a genetic retinal disease called LCA10, which causes blindness. A dysfunctional protein in the eye’s photoreceptors is to blame. Editas scientists have taken retinal cells out of patients with LCA10 and used CRISPR to give those cells proteins that function—in the lab, for now.
Editas is also working on sickle-cell anemia. And, said Bosley, “there are some interesting viral diseases.” But she said Editas is not working on HIV, though its new investor Nikolic had been active in HIV-related investments while at the Gates Foundation.
The funding comes less than two years after Editas was founded. “I was working out of a closet,” says Morgan Maeder, the first scientist Editas hired in October 2013. Now the company has just over 40 employees.
Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.Subscribe today